A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab. The optimal duration of eculizumab in treating patients with aHUS remains poorly defined. Methods: We conducted a multicenter retro...
Saved in:
Main Authors: | Saeed AlZabali (Author), Sawsan AlBatati (Author), Khawla Rahim (Author), Hassan Faqeehi (Author), Abubaker Osman (Author), Abdulaziz Bamhraz (Author), Mohammed A. Saleh (Author), Jameela A. Kari (Author), Majed Aloufi (Author), Loai Eid (Author), Haydar Nasser (Author), Abubakr Imam (Author), Entesar AlHammadi (Author), Omar Alkandari (Author), Mohammed Al Riyami (Author), Sidharth Sethi (Author), Christoph Licht (Author), Khalid A. Alhasan (Author), Abdulkarim AlAnazi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study
by: Abdulaziz A. Bamhraz, et al.
Published: (2020) -
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
by: Richard Kelly, et al.
Published: (2009) -
Revisiting VR training in developmental disorders, is it a friend or foe? A scoping systematic review of randomized controlled trials
by: Antoine Fakhry AbdelMassih, et al.
Published: (2024) -
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
by: Al-Ani F, et al.
Published: (2016) -
Eculizumab in kidney diseases
by: Fatemeh Pour-, et al.
Published: (2024)